Given the proposed mechanisms of SGLT2 inhibitors beyond glycemic control—such as blood pressure reduction, anti-inflammatory and antifibrotic effects, the improvement of endothelial function, and reductions in vascular tone [15]—it is conceivable that microvascular alterations associated with sensorineural hearing loss and tinnitus may be positively influenced by these agents. The gene discussed is SLC5A2; the disease is sensorineural hearing loss disorder.